Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pamrevlumab (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Therapeutic Use
Acronyms ZEPHYRUS; ZEPHYRUS-1
Sponsors FibroGen

Most Recent Events

22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society.
08 Dec 2023 Status changed from active, no longer recruiting to discontinued.
26 Jun 2023 According to a FibroGen media release, company plans to communicate the results of the ZEPHYRUS-1 study at an upcoming medical forum.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com